PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms

Subjects

Subjects :

Pulmonary and Respiratory Medicine
First line treatment
Oncology
Bevacizumab
Egfr mutation
business.industry
medicine
Cancer research
business
medicine.drug
EGFR inhibitors

Details

ISSN :

15560864

Volume :

14

Database :

OpenAIRE

Journal :

Journal of Thoracic Oncology

Accession number :

edsair.doi...........2f9f79d2665335accf77f6e2bd103fe3

Full Text :

https://doi.org/10.1016/j.jtho.2019.09.133